Logo Image
News
Academy
Publications
All PublicationsE-Books
Media
Editorial PodcastsEditorial VideosPeer ExchangePractice AcademyShortsSponsored PodcastsSponsored Videos
More
Conferences
Conference CoverageConference Listing
Columns
All ColumnsA Closing ThoughtClinical Trial InsightsView from BrusselsView from Washington
Resources
AdvertiseBlogsEventsFront & CenterPartner PerspectivesWhite Papers
Events
Webcasts
Event Calendar

Subscribe

  • News
  • Academy
  • Publications
  • Media
  • Conferences
  • Columns
  • Resources
  • Events
  • Subscribe
  • Event Calendar
  • Clinical Operations & Strategy
    • Decentralized Clinical Trials
    • Trial Design
    • Investigative Sites
    • CRO/Sponsor
    • Risk-Based Monitoring
    • Protocol Design
    • Clinical Trial Supply Chain
    • Study Start-Up
    • Early Phase Development
  • DEI
    • Industry Initiatives
    • Diversity Action Plans
    • Recruitment
  • Data Management
    • Analytics
    • Electronic Data Capture
    • Real World Evidence
    • Metrics & Benchmarks
  • Patient Participation
    • Integrated Research
    • CRAACO
    • Enrollment
  • Regulatory
    • Institutional Review Board & Ethics Committee
    • FDA
    • EMA
  • Technology
    • Artificial Intelligence/Machine Learning
    • eClinical
    • mHealth
Spotlight -
Conference Coverage|
Peer Exchange|
DE&I|
Editorial Videos|
Clinical Operations & Strategy|
Patient Participation
Advertisement

Dan Manak

Advertisement

Articles by Dan Manak

Modal Value Guided Clinical Trial Design Effectively Reduces Protocol Amendments

ByGen Li, PhD, MBA,Dan Manak,Jonathan Peachey
April 13th 2021

Analysis of 330,000 clinical trials calls for improved protocol design process.

Advertisement

Latest Updated Articles

  • Modal Value Guided Clinical Trial Design Effectively Reduces Protocol Amendments
    Modal Value Guided Clinical Trial Design Effectively Reduces Protocol Amendments

    April 13th 2021



Advertisement
Advertisement

Trending on Applied Clinical Trials Online

1

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

2

ACT Brief: Simplifying Trials Through Selective Safety Data, AI-Driven Site Partnerships, and Biopharma Strategic Pivots

3

ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion

4

Bringing the Voice of Clinical Practice and Patients into Drug Development

5

ACT Brief: Multimodal AI Systems Architecture, Trust-Based Trial Recruitment, and Big Pharma AI Transformation

  • About
  • Advertise
  • Contact Us
  • Editorial Contacts
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Applied Clinical Trials
  • BioPharm International
  • Cannabis Science and Technology
  • Chromatography Online
  • Nutritional Outlook
  • Pharmaceutical Commerce
  • Pharmaceutical Executive
  • Pharm Tech
  • Spectroscopy Online
  • Turbo Machinery Magazine
IS1
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us